# Merck Animal Health Ventures

Merck Animal Health Ventures is a Venture Capital based in Rahway, United States.

## Overview

- **Organization type:** Venture Capital
- **Headquarters:** Rahway, United States
- **Region:** North America
- **Address:** Rahway, NJ, United States
- **Founded:** 2017
- **Assets under management:** Undisclosed
- **Website:** www.merck-animal-health.com
- **LinkedIn:** https://www.linkedin.com/company/merck-animal-health

## Regulatory record

- **Reports private funds:** No

## About

Merck Animal Health - Information on veterinary products, technologies and veterinary services that truly advance animal healthcare.

## Sectors

- Animal Health
- Biopharma
- AgriTech & FoodTech

## Questions

### How does Merck Animal Health Ventures source and win deals?

The team originates through the division's scientific network, academic partnerships, and the pipeline of its six species-specific business units. Because Merck Animal Health already has commercial operations in more than 50 countries, portfolio candidates often surface from veterinarians, farmers, or regional distributors who have tested a technology in the field. That real-world evidence, coupled with Merck's internal R&D and regulatory-affairs capability, allows the venture arm to diligence and price rounds faster than a stand-alone financial VC.

### Is this a third-party fund or a corporate balance-sheet effort?

It is a corporate venture arm investing off Merck Animal Health's own balance sheet. There are no outside limited partners, and capital is evergreen — returns recycle back to the parent rather than to a closed-end fund. This single-LP structure means the venture team can hold positions through regulatory approval and commercial launch without needing to exit on a fixed time horizon.

### What species and therapeutic areas does the venture cover?

The mandate spans all six species platforms of the parent organization: companion animal, equine, swine, ruminants, poultry, and aqua. Within those platforms, the venture looks for novel vaccines, next-generation parasiticides, digital-animal-health tools, and diagnostics. The parent's own recent pipeline — BRAVECTO QUANTUM for dogs, BOVILIS NASALGEN-C for calves, and ISKNV vaccines for tilapia — provides a good proxy for the technical scope that interests the venture team.

## Related profiles

- [Mercia Asset Management](https://altss.com/profile/mercia-fund-management)
- [Merck China](https://altss.com/profile/merck-china)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/merck-animal-health-ventures

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology